New drug to treat chronic drooling

New Drug to Treat Chronic Drooling

The US Food and Drug Administration (FDA) recently approved a drug called Xeomin (incobotulinumtoxinA), to treat excessive drooling in adults.

Excessive drooling, or chronic sialorrhea, is a common symptom of cerebral palsy (CP), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Sialorrhea can involve problems with swallowing and difficulty controlling facial muscles.New drug to treat chronic drooling

Xeomin is the first FDA-approved neurotoxin for treating sialorrhea. It was approved under priority review, which is a process used for drugs that have the potential to provide significant benefits to people with serious conditions. Xeomin was previously approved to treat cervical dystonia, blepharospasm, and upper limb spasticity.

Xeomin can be delivered to muscles and glands through an injection. To treat sialorrhea, it is injected into glands. For other uses, it is injected into muscles.

Currently, Xeomin is only approved for adults; it is not yet known whether it is safe and effective for people under the age of 18.

Potential side effects of Xeomin include the following (this is not a complete list):

  • Issues with swallowing, speaking, or breathing. People with certain swallowing or breathing problems may be at greater risk for experiencing complications.
  • Botulism. This is a condition in which the toxin effects spread away from the injection site, and cause symptoms in other parts of the body, such as muscle weakness, vision problems, drooping eyelids, or bladder control issues.
  • Death

In people using Xeomin to treat chronic sialorrhea, the most common side effects are:

  • Needing to have a tooth extracted
  • Dry mouth
  • Diarrhea
  • High blood pressure

To learn more about Xeomin, click here.

Other Recent Blog Posts

Share This Post

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *